Purchased shares of common stock and Series C Warrants in the Private Placement through affiliated entities.
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Jayson Rieger
Also a director
President and Chief Executive Officer
|
50 | Not stated | $741,403 | |
|
John J. Kirby
Interim Chief Financial Officer
|
54 |
Since 2024
2 years
|
$614,600 | |
|
David Zawitz
Chief Operating Officer, Chief Legal Officer and Secretary
|
45 | Not stated | Not reported | |
|
Noah Rosenberg
CMO
Title from the Form 4 dated Aug 17, 2026
|
59 | Not stated | $347,588 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchased shares of common stock and Series C Warrants in the Private Placement through affiliated entities.
Purchased shares of common stock and Series C Warrants in the Private Placement.
Purchased shares of common stock and Series C Warrants in the Private Placement.
Purchased shares of common stock and Series C Warrants in the Private Placement.
Purchased shares of common stock and Series C Warrants in the Private Placement.
Appointed as a Class I director designated by Caligan in connection with the Private Placement, with a continuing board designation right for Caligan.
Clinical service agreement under which Clinical Enrollment provides recruiting support services for the VP-315 clinical trial.
Loading...